Stifel analyst Justin Keywood raised the firm’s price target on Knight Therapeutics (KHTRF) to C$7.45 from C$6.25 and keeps a Buy rating on the shares.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.